Fate Therapeutics (NASDAQ:FATE) & Alumis (NASDAQ:ALMS) Critical Survey

Alumis (NASDAQ:ALMS – Get Free Report) and Fate Therapeutics (NASDAQ:FATE – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Valuation and Earnings

This table compares Alumis and Fate Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alumis $7.40 million 88.42 -$243.32 million ($3.53) -1.43
Fate Therapeutics $6.65 million 20.57 -$136.32 million ($1.03) -1.09

Fate Therapeutics has lower revenue, but higher earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Alumis has a beta of -0.28, indicating that its share price is 128% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.65, indicating that its share price is 165% more volatile than the S&P 500.

Insider and Institutional Ownership

97.5% of Fate Therapeutics shares are held by institutional investors. 33.7% of Alumis shares are held by insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Alumis and Fate Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alumis -5,844.54% -89.77% -71.50%
Fate Therapeutics -1,941.09% -73.92% -45.16%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Alumis and Fate Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alumis 1 1 11 1 2.86
Fate Therapeutics 1 1 4 0 2.50

Alumis currently has a consensus target price of $31.27, indicating a potential upside of 518.77%. Fate Therapeutics has a consensus target price of $5.80, indicating a potential upside of 415.56%. Given Alumis’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Alumis is more favorable than Fate Therapeutics.

Summary

Fate Therapeutics beats Alumis on 8 of the 15 factors compared between the two stocks.

About Alumis

(Get Free Report)

Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.

About Fate Therapeutics

(Get Free Report)

Fate Therapeutics is a clinical-stage biotechnology company based in San Diego, California. It develops cellular immunotherapies using induced pluripotent stem cells (iPSCs), which can be engineered and used to produce populations of therapeutic cells. The company’s research focuses on off-the-shelf cell therapies, including natural killer (NK) cell and T-cell programs designed to target cancer. Its approach aims to create standardized therapies that do not require cells to be collected from each individual patient.

Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.